Selected data models

You must log in to select data models for download or further analysis.

20 Search results.
Relevance Rating New first Old first

GBM Neurocognitive Evaluation Summary Form (CS) RTOG 0825 Phase III

- 1/9/15 - 1 form, 6 itemgroups, 39 items, 1 language
Itemgroups: Header Module, Hopkins Verbal Learning Test - Revised Administration, Trail Making Test Part A, Trail Making Test Part B, Contolled Oral Word Association (COWA), Footer
RTOG 0825 Phase III GBM Neurocognitive Evaluation Summary Form (CS) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5BE60D36-11E5-00FF-E044-0003BA3F9857

Brain and Central Nervous System Tumors NCT00304031 Treatment - RTOG-0525 T1: Radiotherapy Form - 2388768v1.0 - RTOG-0525 T1: Radiotherapy Form

- 1/9/15 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: MODULE 1
RTOG-0525 T1: RadiotherapyForm Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FE14506D-7AFC-4C09-E034-0003BA3F9857

Hypofractionation for Breast Cancer NCT01948726 - Eligibility Criteria

- 6/15/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01948726 Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies. Investigators initiated this multicenter phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer under the hypothesis that the ratio of patients with acute radiogenic toxicity Grad II according NCI-CTCAE amounts maximum 20%.

Eligibility Breast Cancer NCT00897702

- 2/22/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00897702

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Radiotherapy Form (T1) - 2796276v1.0 - RTOG 0825 Phase III GBM Radiotherapy Form (T1)

- 1/9/15 - 1 form, 1 itemgroup, 21 items, 1 language
Itemgroup: Radiotherapy Form
RTOG 0825 Phase III GBM Radiotherapy Form (T1) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5A7BC3C4-2306-2CB9-E044-0003BA3F9857

Breast Cancer Radiation Therapy Report NSABP B-36 NCT00087178 - Radiation Therapy Report Breast Cancer NCT00087178

- 5/20/15 - 1 form, 4 itemgroups, 17 items, 1 language
Itemgroups: Header, Radiation therapy, Whole Breast Irradiation, Chest Wall Irradiation
NSABP Protocol B-36 Radiation Therapy Report Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer NCT00087178 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C87B5190-AA07-59CE-E034-0003BA12F5E7

E3F05 Radiation Therapy Form NCT00978458

- 6/16/15 - 1 form, 6 itemgroups, 24 items, 1 language
Itemgroups: Header Module, Patient demographics, Vital Status, Therapy Administered, Non-Protocol Therapy, Comments
E3F05 Radiation Therapy Form NCT00978458 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6C1889F9-D047-5474-E040-BB89AD431A23

Radiation Therapy Reporting Form N0577

- 1/8/15 - 1 form, 5 itemgroups, 26 items, 1 language
Itemgroups: Header Module, Brain, Technique, Treatment Areas, Dose and Time, Footer Module
North Central Cancer Treatment Group N0577 Radiation Therapy Reporting Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C094A4D-BDDC-3997-E044-0003BA3F9857

Breast Cancer NCT01272037 Treatment - S1007 Radiation Therapy Form (S1007RAD) - 3139641v1.0 - S1007 Radiation Therapy Form (S1007RAD)

- 1/9/15 - 1 form, 6 itemgroups, 30 items, 1 language
Itemgroups: Header Module, Radiation Therapy, Site Irradiated, Targeted Regions of Treatment, Partial Breast Irradiation Method, Comments
S1007 Radiation Therapy Form (S1007RAD) Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=90C9DFFB-2367-84DB-E040-BB89AD437DC2

NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for Patients Randomized to PBI (Group 2 Patients Only)

- 7/5/15 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Header, Radiation Therapy Report
NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for Patients Randomized to PBI (Group 2 Patients Only) Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E74A3E53-F9E9-58E3-E034-0003BA3F9857

CALGB: ADJUVANT RADIOTHERAPY REPORT FORM 2 NCT00041119

- 6/21/15 - 1 form, 3 itemgroups, 16 items, 1 language
Itemgroups: Header, Patient demographics, Radiation Treatment
CALGB: ADJUVANT RADIOTHERAPY REPORT FORM 2 NCT00041119 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E03851EE-EEDC-5498-E034-0003BA12F5E7

CALGB: 49808 RADIOTHERAPY REPORT FORM NCT00016276

- 6/3/15 - 1 form, 4 itemgroups, 25 items, 1 language
Itemgroups: CALGB clinical trial administrative data, Patient clinical trial data, RADIATION TREATMENT, Comments
CALGB: 49808 RADIOTHERAPY REPORT FORM NCT00016276 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9E35395C-8724-227A-E034-080020C9C0E0

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial